Ser567
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser567  -  ERK5 (human)

Site Information
VLsDNDRsLLERWTR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 20572700

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 ) , mutation of modification site ( 2 )
Relevant cell line - cell type - tissue:
HeLa (cervical) ( 2 )

Upstream Regulation
Treatments:
nocodazole ( 2 ) , sorbitol ( 2 )

Downstream Regulation
Effects of modification on ERK5:
enzymatic activity, inhibited ( 2 ) , intracellular localization ( 2 )
Effects of modification on biological processes:
transcription, altered ( 2 )

References 

1

Gilley R, et al. (2012) CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIM(EL). Cell Signal 24, 170-80
21924351   Curated Info

2

Iñesta-Vaquera FA, et al. (2010) Alternative ERK5 regulation by phosphorylation during the cell cycle. Cell Signal 22, 1829-37
20667468   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.